CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionProfit margin is 69.6%, higher than 95% of its Biotechnology peers (median -45.7%)
- FinancialsAltman Z-Score -3.07: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
710.16MUSDvs all stocks (USD)
Trailing P/E
25.59xvs Biotechnology peers
Revenue (TTM)
48.55MUSDvs all stocks (USD)
Profit Margin
69.63%vs Biotechnology peers
Beta
0.8650xvs all stocks
52-Week Change
57.65%vs all stocks
Market Capitalization
710.16MUSDvs all stocks (USD)
Enterprise Value
562.48MUSDvs all stocks (USD)
Trailing P/E
25.59xvs Biotechnology peers
Forward P/E
18.77xvs Biotechnology peers
PEG Ratio
0.1279xvs Biotechnology peers
Price to Sales (TTM)
14.63xvs Biotechnology peers
Price to Book (MRQ)
5.15xvs Biotechnology peers
Enterprise to Revenue
11.58xvs Biotechnology peers
Enterprise to EBITDA
67.81xvs Biotechnology peers
Profit Margin
69.63%vs Biotechnology peers
Operating Margin
-3.90%vs Biotechnology peers
Return on Assets (TTM)
1.28%vs Biotechnology peers
Return on Equity (TTM)
34.23%vs Biotechnology peers
Revenue (TTM)
48.55MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.03USDUpdated Jul 19, 2026Quarterly Revenue Growth
-22.60%vs Biotechnology peers
Gross Profit (TTM)
48.09MUSDvs all stocks (USD)
EBITDA (TTM)
19.37MUSDvs all stocks (USD)
Net Income (TTM)
19.93MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
88.60%vs Biotechnology peers
Operating Cash Flow (TTM)
6.79MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-13.07MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
11.66MUSDFY2025 · Dec 31, 2025Operating Income
11.38MUSDvs all stocks (USD)
Pre-tax Income
31.82MUSDFY2025 · Dec 31, 2025Income Tax Expense
103.00KUSDFY2025 · Dec 31, 2025Net Income
31.71MUSDFY2025 · Dec 31, 2025EBIT
44.85MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
19.37MUSDFY2025 · Dec 31, 2025Research & Development
1.71MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
36.09MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-40.49MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
13.03MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
31.71MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
7.67MUSDFY2025 · Dec 31, 2025Operating Cash Flow
13.35MUSDFY2025 · Dec 31, 2025Free Cash Flow
13.35MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.97M of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads -17.85M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
133.71MUSDFY2025 · Dec 31, 2025Income Tax Paid
277.00KUSDFY2025 · Dec 31, 2025Interest Paid
11.91MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
31.71MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.97MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
103.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.27MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-26.09MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.43MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.19MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Net Intangibles (CF)
-20.73MUSDFY2025 · Dec 31, 2025Net Acquisitions
8.31MUSDFY2025 · Dec 31, 2025Purchase of Investments
-99.00KUSDFY2025 · Dec 31, 2025Sale of Investments
7.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
56.40MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
71.61MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-10.60MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-16.71MUSDFY2025 · Dec 31, 2025Common Dividends Paid
-5.47MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.07MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-31.51MUSDFY2025 · Dec 31, 2025Shares Outstanding
11.91MSharesUpdated Jul 19, 2026Float Shares
4.80MSharesUpdated Jul 19, 2026Shares Short
914.94KSharesUpdated Jul 19, 2026Short Ratio
6.43daysvs all stocks
Short % of Shares Outstanding
9.29%vs all stocks
% Held by Insiders
2.33%vs all stocks
% Held by Institutions
85.33%vs all stocks
Total Cash (MRQ)
86.09MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.87USDUpdated Jul 19, 2026Total Debt (MRQ)
124.73MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.10xvs Biotechnology peers
Current Ratio (MRQ)
3.59xvs Biotechnology peers
Book Value per Share (MRQ)
7.79USDUpdated Jul 19, 2026Total Assets
272.70MUSDvs all stocks (USD)
Total Current Assets
117.26MUSDFY2025 · Dec 31, 2025Total Liabilities
188.76MUSDFY2025 · Dec 31, 2025Total Non-current Assets
155.44MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
153.94MUSDFY2025 · Dec 31, 2025Total Current Liabilities
34.82MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
82.91MUSDFY2025 · Dec 31, 2025Other Short-term Investments
382.00KUSDFY2025 · Dec 31, 2025Accounts Receivable
4.90MUSDFY2025 · Dec 31, 2025Accounts Payable
2.21MUSDFY2025 · Dec 31, 2025Short-term Debt
14.99MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.27MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.04MUSDFY2025 · Dec 31, 2025Long-term Debt
116.56MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
14.06MUSDFY2025 · Dec 31, 2025Common Stock (Book)
89.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.22BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
83.94MUSDvs all stocks (USD)
52-Week Low
22.29USDUpdated Jul 19, 202652-Week High
45.22USDUpdated Jul 19, 202652-Week Change
57.65%vs all stocks
Beta
0.8650xvs all stocks
50-Day MA
42.01USDUpdated Jul 19, 2026200-Day MA
33.53USDUpdated Jul 19, 2026Avg 10-Day Volume
799.24KSharesUpdated Jul 19, 2026Avg 30-Day Volume
365.84KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
1.57USDUpdated Jul 19, 2026Other Income / Expense
33.46MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 69.6%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 0.70Industry median: -0.46Industry P95: 0.43Peers compared: 261
Return on equity is 34.2%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.34Industry median: -0.22Industry P95: 0.23Peers compared: 261
Debt-to-equity is 1.1×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 1.10Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 19,932,000Operating Cash Flow (USD, TTM): 6,794,000
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.59Altman Z-Score: -3.07
Financial Health
Altman Z-Score -3.07: distress zoneCritical
Altman Z-Score: -3.07
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Vireo Growth Inc.
Tier 1ProductionApproval-Gated PipelineFlowInterface
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
R&G Pharmastudies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Hunan Yujing Machinery Co., Ltd.
1 interpretationCash-Flow Ratios Elevated
Mastercard Incorporated
1 interpretationCash-Flow Ratios Elevated
Johnson Fine Chemical Co., Ltd.
1 interpretationCash-Flow Ratios Elevated